Zhen Hong

Zhen Hong

Auto-generated profile, based on publicly available information

Zhen Hong

Huashan Hospital, Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2021 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
SLShichuo Li
Shichuo Li
YWYuping Wang
Yuping Wang
WWWenzhi Wang
Wenzhi Wang
DZDong Zhou
Dong Zhou
HZHui Zhang
Hui Zhang
ZHZhen Hong
Zhen Hong
This article describes “the national comprehensive governance for epilepsy prevention and control in China” as an example of a strategic working program for the prevention and control of epilepsy at a national level. The comprehensive governance includes 10 key elements: epilepsy centers' consortium and three tier diagnosis/treatment network; rural and urban community projects on epilepsy care; awareness, publicity, and education; big data platform; development of telemedicine; team and capacity building; strengthening epilepsy research; developing and strengthening partnership; coordination with government; and international collaboration.

1 July 2013 in Neurological Research
Verified
Journal Article
Closed access
LXLan Xu
Lan Xu
YHYong Hao
Yong Hao
XWXunyi Wu
Xunyi Wu
PYPeimin Yu
Peimin Yu
GZGuoxing Zhu
Guoxing Zhu
ZHZhen Hong
Zhen Hong
Objective: Inwardly rectifying K+ (Kir) channel, Kir2·3, has been found down-regulated in the hippocampus of chronic temporal lobe epileptic (cTLE) patients which may underline the mechanism of epilepsy. Tenidap is an agonist of Kir2·3. However, the effect of tenidap on cTLE remains obscure. The aim of the present study was to observe the relationship between Kir2·3 and the pathogenesis of cTLE, and to explore the potential effect of Kir agonists as anti-epileptic drugs. Methods: The pilocarpine temporal lobe epilepsy (TLE) rat model was established and status epilepticus (SE) was induced in rats. The rats were divided into four groups based on time points (0 hours, 6 hours, 72 hours, and two weeks) after SE termination. The dynamic changes in Kir2·3 mRNA and protein expression in the hippocampus were detected at each time point by reverse transcription polymerase chain reaction (RT-PCR) and western blotting to determine an appropriate time for further intervention and observation. Then, tenidap was administered and its effect on the expression of Kir2·3 mRNA/protein and the electroencephalogram (EEG) wave was documented at predetermined time points. Results: The pattern of Kir2·3 mRNA and protein expression was bimodal, as it increased immediately after SE and declined at two weeks, when compared with the control group. Down-regulation of the Kir channels may lead to an impaired clearance of K+ ions from the extracellular space and result in a stronger neuronal depolarisation. Two weeks after SE may be a reversal point. Spontaneous recurrent seizures (SRS) appeared at the two-week point, indicating that chronic epilepsy had occurred. Tenidap up-regulated expressions of both Kir2·3 channel mRNA and protein, which may help to maintain the resting membrane potential (RMP) and hyperpolarisation of the cells. Conclusions: Our results suggest that the down-regulation of the Kir2·3 channel expression might contribute to the pathogenesis of TLE, which may be ameliorated by the administration of tenidap.

1 January 2021 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
KPKee Hyung Park
Kee Hyung Park
YYYoungSoon Yang
YoungSoon Yang
CCChristopher Chen
Christopher Chen
YSYong Soo Shim
Yong Soo Shim
JDJacqueline C. Domingueze
Jacqueline C. Domingueze
SKSangYun Kim
SangYun Kim
Park KH, et al. J Clin Neurol. 2021 Jul;17(3):376-384. https://doi.org/10.3988/jcn.2021.17.3.376

27 October 2025 in Epilepsia
Verified
Journal Article
Open access
Sang Kun LeeSang Kun Lee
Sang Kun Lee
PYPeimin Yu
Peimin Yu
ECEunyeong Choe
Eunyeong Choe
LFLouis Ferrari
Louis Ferrari
KHKyoung Heo
Kyoung Heo
SMSunita N. Misra
Sunita N. Misra
Objectives: This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures. Methods: Adults 18–70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic) during an 8‐week baseline, despite treatment with 1–3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18‐week titration phase and a 6‐week maintenance phase. The primary efficacy analysis was a hierarchical step‐down comparison of the percent change from baseline in 28‐day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day. Results: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was −25.9% for placebo vs −42.6%, −78.3%, and −100% for cenobamate 100, 200, and 400 mg/day, respectively (all p 's < .001). During the 12‐week period encompassing the last 6 weeks of titration and the 6‐week maintenance phase (secondary outcome), the median percent change in seizure frequency was −20.1% for placebo vs −42.6%, −77.1%, and −89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure‐free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12‐week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment‐emergent adverse events in cenobamate patients (≥20%) were dose‐related dizziness and somnolence. Significance: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose‐related fashion and was generally well tolerated.

15 July 2019 in Neuroepidemiology
Verified
Journal Article
Closed access
FWFei Wang
Fei Wang
JMJames A. Mortimer
James A. Mortimer
DDDing Ding
Ding Ding
JLJianfeng Luo
Jianfeng Luo
QZQianhua Zhao
Qianhua Zhao
ZHZhen Hong
Zhen Hong
Introduction: An important index of brain reserve is the maximal attained brain size, which can be estimated by measuring the head circumference (HC). We investigated the association of HC and education with incident dementia in a population-based study of Chinese older adults. Methods: We conducted a prospective follow-up study of 1,659 non-demented participants with a mean age of 71.5 years. Characteristics and anthropometry of the participants were collected at baseline. Consensus diagnoses for dementia were made using DSM-IV criteria based on functional, neurological, and neuropsychological assessments. Results: We identified 168 new-onset dementia cases after a mean of 5.2 years of follow-up. Participants with smaller HC combined with low educational attainment had a significantly higher risk of incident dementia than those with larger HC who had completed more than 12 years of education (adjusted hazard ratio 4.48, 95% CI 2.47–8.12). Discussion/Conclusion: Our results suggest that smaller HC in combination with low education leads to a markedly increased risk of dementia.

6 October 2017 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
PWPing Wang
Ping Wang
KCKeliang Chen
Keliang Chen
YGYuehua Gu
Yuehua Gu
QGQihao Guo
Qihao Guo
ZHZhen Hong
Zhen Hong
QZQianhua Zhao
Qianhua Zhao
Background: Previous studies have suggested that the expression of Aβ and clusterin is positively correlated. However, the causal relationship between Aβ and clusterin has not been exactly clarified. Methods: In this study, primary hippocampal neurons were treated with Aβ42; clusterin mRNA and protein expression was assessed. Furthermore, we evaluated Aβ and clusterin protein expression in the brains of APP/PSEN1 mice, as well as serum clusterin concentration. Results: We observed here that the exposure of primary hippocampal neurons to Aβ42 induced an overexpression of intracellular clusterin, but the level of clusterin in supernatants was not changed. Moreover, in APP/PSEN1 mice, there was a significant increase in intracellular clusterin in cortex and hippocampus, compared to age-matched WT mice, while serum clusterin level in APP/PSEN1 mice and in WT mice has no significant difference. Conclusion: Aβ42 upregulated intracellular clusterin, but secretory clusterin did not change. These findings reveal that clusterin is upregulated by Aβ and is responsive to AD pathology, although plasma clusterin concentration is not evidenced to be a stand-alone biomarker for AD.